SpringWorks
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout
Merck KGaA closes in on SpringWorks deal at $3.5B price point
SpringWorks, Acquisition (action), KGaA, Infrequent, Gomekli, deal, Merck
SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors
SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor
FDA Approves SpringWorks’ Gomekli for Adult and Pediatric NF1-PN Patients
Gomekli, mirdametinib, neurofibromatosis type 1, plexiform neurofibromas, FDA approval, SpringWorks Therapeutics, MEK inhibitor
Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio
Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry
Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics
Merck KGaA, SpringWorks Therapeutics, acquisition talks, biopharmaceutical industry, rare diseases, cancer treatments, Ogsiveo